SUPPORTING INFORMATION

Differential Role of Serines and Threonines in Intracellular Loop 3 and C-terminal Tail of the Histamine H_4 Receptor in β -arrestin and G Protein-Coupled Receptor Kinase Interaction, Internalization, and Signaling.

Eléonore W.E. Verweij¹, Betty Al Araaj¹, Wimzy R. Prabhata¹, Rudi Prihandoko², Saskia Nijmeijer¹, Andrew B. Tobin², Rob Leurs¹, Henry F. Vischer¹*

¹Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.

²Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.

Pages: 6

Figures: 6

Table of contents:

Figure S1. Pharmacological characterization of WT H₄R-Rluc8 fusion protein.

Figure S2. JNJ7777120 and thioperamide antagonize histamine induced β -arrestin2 recruitment

Figure S3. β -arrestin1/2 protein levels after knockdown by siRNA.

Figure S4. Effect of clobenpropit on the interaction between H₄R and GRKs

Figure S5. Pharmacological characterization of IL3 and/or CT H₄R mutants and BRET acceptor expression.

Figure S6. H₄R-induced ERK1/2 activation and cellular impedance.



Figure S1. Pharmacological characterization of WT H₄R-Rluc8 fusion protein. Total and non-specific binding of increasing concentrations [³H]histamine to HEK293T cell homogenates expressing HA-H₄R (A) or H₄R-RLuc8 (B). Graphs are representative of 3 independent experiments that were performed in triplicate. Data are shown as mean \pm SEM. Inhibition of forskolin-induced CRE-driven reporter gene activity in HEK293T cells expressing H₄R-RLuc8 or HA-H₄R in response to increasing concentrations histamine (B) or 100 nM histamine following pretreatment with 100 ng/mL PTx for 16 h (C). Data are shown as mean \pm SEM from at least 3 independent experiments performed in triplicate and presented as fold over vehicle-stimulated cells (i.e. basal).



Figure S2. β -arrestin2 recruitment to H₄R. (A-C) JNJ7777120 (A) and thioperamide (B) inhibited histamine-induced β -arrestin2 recruitment in HEK293T cells coexpressing H₄R-Rluc8 and β -arrestin2-mVenus in a concentration-dependent manner. Data are shown as mean ± SEM from 3 independent experiments performed in duplicate. Ligand-induced BRET changes (Δ BRET) were calculated by subtracting BRET ratio of vehicle-treated cells.



Figure S3. β -arrestin1/2 protein levels after knockdown by siRNA. (A) Representative immunoblot to evaluate β -arrestin1/2 expression in HEK293T cells cotransfected with H₄R-Rluc8 and Venus-Rab5a encoding plasmids, and scrambled or β -arrestin1/2 siRNA. STAT3 expression was used as loading control. (B) Grouped densitometric measurements from 3 independent experiments using ImageJ software (National Institutes of Health, MD, USA). Bars show means \pm SEM from 3 independent experiments. Scatter plots show individual data. Statistical difference (p < 0.05) compared to scrambled siRNA treated cells was determined using unpaired t-test and is indicated by an asterisk (*).



Figure S4. Effect of clobenpropit on the interaction between H_4R and GRKs. BRET measurements in HEK293T cells expressing H_4R -Rluc8 in combination with GRK2-mVenus, GRK3-mVenus, GRK5-mVenus, or GRK6-mVenus, after 30 min incubation with increasing concentrations clobenpropit. Data are shown as mean \pm SEM from 3 independent experiments performed in triplicate. Ligand-induced BRET changes (Δ BRET) were calculated by subtracting BRET ratio of vehicle-treated cells.



Figure S5. Pharmacological characterization of IL3 and/or CT H₄R mutants and BRET acceptor expression. Total and non-specific binding of increasing concentrations [³H]histamine to HEK293T cell homogenates expressing H₄R-Rluc8 (A), H₄R-IL3-Rluc8 (B), H₄R-CT-Rluc8 (C), or H₄R-IL3/CT-Rluc8 (D). Graphs are representative of 3 independent experiments that were performed in triplicate. Data are shown as mean \pm SEM. BRET measurements in HEK293T cells expressing H₄R-Rluc8 WT or mutants in combination with β-arrestin2-mVenus (E) or β-arrestin1-eYFP (F), after 30 min incubation

with increasing concentrations histamine. Data are shown as mean \pm SEM from 3 independent experiments performed in triplicate. Ligand-induced BRET changes (Δ BRET) were calculated by subtracting BRET ratio of vehicle-treated cells. (G-M) Fluorescence measurements (excitation at 485 nm and emission at 535 nm) to detect expression levels of β -arrestin2-mVenus (G), β -arrestin1-eYFP (H), Venus-Rab5a (I), GRK2-mVenus (J), GRK3-mVenus (K), GRK5-mVenus (L), GRK6-mVenus (M) in HEK293T cells that co-express H₄R-Rluc8, H₄R-IL3-Rluc8, H₄R-CT-Rluc8, or H₄R-IL3/CT-Rluc8. Data are shown as mean \pm SEM from 3 independent experiments and expressed as fold over WT H₄R-Rluc8.



Figure S6. H₄R-induced ERK1/2 activation and cellular impedance. HA-tagged H₄R was stably expressed in HEK293 cells. Histamine-induced ERK1/2 phosphorylation was measured using an HTRF-based detection kit after 5 min incubation (A) and following pretreatment with 100 ng/mL PTx for 16 h or 100 μ M H₄R antagonist VUF10558 (B). Data are shown as mean \pm SEM from 3 independent experiments in duplicate, and presented as histamine-induced HTRF changes (Δ HTRF) by subtracting the HTRF ratio of vehicle-treated cells. Statistical differences between histamine-induced ERK1/2 in the absence or presence of PTx or VUF10558 were analyzed using one-way ANOVA with Dunnett's multiple comparisons test (* *p*<0.05). Cellular impedance changes in response to stimulation with increasing concentrations histamine in time (C) and peak response (D). Data are shown as mean \pm SEM from 4 independent experiments in duplicate.